6Nseir S, Di Pompeo C, Cavestri B, et al. Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pul monary disease: prevalence, risk factors, and outcome [J]. Crit Care Med, 2006,34(12):2959-2966.
7Wilson R. Bacteria, antibiotics and COPD [J]. Eur Respir J,2001,17(5):995- 1007.
8Murphy TF, Sethi S, Niederman MS. The role of bacteria in exacerbations of COPD. A constructive view [J]. Chest,2000,118(1):204-209.
9GOLD Executive Committee[DB/OL].Guidelines:Global Strategy for Diagnosis,Management,and Prevention of COPD,November 2006[2006-11-18].http://www.goldcopd.com/Guidelineitem.asp? l1 =2-12 = 1&intId =989.
10Celli BR,MacNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946.
4Verduri A,Luppi F, D'Amico R,et a/.Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin:a randomized noninferiority tri- al[J].PLoS One,2015,10(3) :e0118241.
5Grolimund E, Kutz A, Marlowe RJ,et a/.Long-term progno- sis in COPD exacerbation:role of biomarkers,clinical vari- ables and exacerbation type [J].COPD, 2015,12 (3) : 295 -305.
6M. Honkinen,E. Lahti,R. ?sterback,O. Ruuskanen,M. Waris.??Viruses and bacteria in sputum samples of children with community-acquired pneumonia(J)Clinical Microbiology and Infection . 2012 (3)
7Catherine H. Pashley,Abbie Fairs,Joseph P. Morley,Shreeya Tailor,Joshua Agbetile,Mona Bafadhel,Christopher E. Brightling,Andrew J. Wardlaw.??Routine processing procedures for isolating filamentous fungi from respiratory sputum samples may underestimate fungal prevalence(J)Medical Mycology . 2012 (4)
